Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor by Tan, Chee Wah et al.
Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan
as an Attachment Receptor
Chee Wah Tan,a Chit Laa Poh,b I-Ching Sam,a,c Yoke Fun Chana,c
Department of Medical Microbiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysiaa; Faculty of Science and Technology, Sunway University, Selangor,
Malaysiab; Tropical Infectious Disease Research and Education Center (TIDREC), Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysiac
Enterovirus 71 (EV-71) infections are usually associated with mild hand, foot, andmouth disease in young children but have
been reported to cause severe neurological complications with highmortality rates. To date, four EV-71 receptors have been
identified, but inhibition of these receptors by antagonists did not completely abolish EV-71 infection, implying that there is an
as yet undiscovered receptor(s). Since EV-71 has a wide range of tissue tropisms, we hypothesize that EV-71 infections may be
facilitated by using receptors that are widely expressed in all cell types, such as heparan sulfate. In this study, heparin, polysul-
fated dextran sulfate, and suramin were found to significantly prevent EV-71 infection. Heparin inhibited infection by all the
EV-71 strains tested, including those with a single-passage history. Neutralization of the cell surface anionic charge by polyca-
tionic poly-D-lysine and blockage of heparan sulfate by an anti-heparan sulfate peptide also inhibited EV-71 infection. Interfer-
ence with heparan sulfate biosynthesis either by sodium chlorate treatment or through transient knockdown ofN-deacetylase/
N-sulfotransferase-1 and exostosin-1 expression reduced EV-71 infection in RD cells. Enzymatic removal of cell surface heparan
sulfate by heparinase I/II/III inhibited EV-71 infection. Furthermore, the level of EV-71 attachment to CHO cell lines that are
variably deficient in cell surface glycosaminoglycans was significantly lower than that to wild-type CHO cells. Direct binding of
EV-71 particles to heparin-Sepharose columns under physiological salt conditions was demonstrated. We conclude that EV-71
infection requires initial binding to heparan sulfate as an attachment receptor.
Human enterovirus 71 (EV-71) belongs to the Enterovirus ge-nus within the family Picornaviridae. The EV-71 genome is a
positive-sense, single-stranded RNA enclosed in an icosahedral
capsid assembled from 60 copies of each of the four structural
proteins, VP1 to VP4 (1).
EV-71 infections usually cause mild hand, foot, and mouth
disease (HFMD), characterized by the development of fever with
rashes on the palms and feet and with oral ulcers (2). EV-71 also
causes severe neurological manifestations, such as aseptic menin-
gitis, brain stem encephalitis, and poliomyelitis-like acute flaccid
paralysis (3). In recent years, EV-71 has emerged as an important
cause of epidemic viral encephalitis in Asia, resulting in high fa-
talities among children below the age of 6 years (3, 4).
Receptor binding is an essential event during viral infection.
The ability to recognize and interact with specific receptors is one
of the factors that contribute to the host range and tissue tropism
of a virus (5). To date, at least four EV-71 receptors have been
reported. The first receptor to be discovered was the human P-
selectin glycoprotein ligand-1 (PSGL-1). PSGL-1 is a sialomucin
membrane protein expressed mainly in leukocytes and was hy-
pothesized to facilitate the viremic phase of EV-71 infection (6).
The second receptor reported was the human scavenger receptor
class B-2 (SCARB2), a type III double-transmembrane protein
located primarily in endosomes but also expressed on the cell sur-
face (7–9). Sialylated glycan was also reported as one of the possi-
ble receptors for EV-71 infection. Removal of sialic acid residues
from plasma membranes was able to protect DLD-1, RD, and
SK-N-SH cells from EV-71 infection (10, 11). Annexin II has re-
cently been identified as another possible receptor for EV-71 in
RD cells. Pretreatment of EV-71 with soluble annexin II resulted
in reduced viral attachment to the cell surface (12). However,
inhibitors that blocked all of the receptors identified failed to in-
hibit EV-71 infection completely (13). This may imply the in-
volvement of one or more EV-71 receptors that have yet to be
discovered.
Our previous study identified a novel antiviral peptide, SP40,
derived from the VP1 capsid protein (14). This peptide was found
to contain a heparan sulfate-specific glycosaminoglycan (GAG)
binding domain (-RRKV-), and the positively charged amino ac-
idswere found to be critical for antiviral properties.Wepostulated
that SP40 interacted with heparan sulfate and blocked EV-71 at-
tachment (14). Similarly, bovine and human lactoferrin exhibited
antiviral activities against EV-71 when tested in vitro and in vivo,
possibly due to direct interactionwith heparan sulfate, resulting in
interference with EV-71 binding (15, 16). In a recent study, hep-
arin and heparan sulfate were reported to exhibit antiviral activi-
ties against EV-71 infection (17). These findings led us to hypoth-
esize that surface heparan sulfate might play an important role in
EV-71 attachment.
GAGs are negatively charged linear polysaccharides composed
of hexosamine/hexuronic acid repeats. GAGs acquire negative
charges through N- and O-sulfation of the carbohydrate moieties
(18). The types of GAG include heparin, heparan sulfate, and
chondroitin sulfate. GAG-ligand interactions are complex and are
characterized either by merely electrostatic forces or by specific
interactions (19). Many viral pathogens, such as herpes simplex
virus (20, 21), HIV (22, 23), dengue virus (24), human papilloma-
virus (25), vaccinia virus (26), Theiler’smurine encephalomyelitis
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virus (TMEV) (27), adeno-associated virus type 2 (28, 29), hepa-
titis B virus (30), hepatitis C virus (31), Sindbis virus (32), echo-
virus (33), coxsackievirus B3 and A9 (34, 35), and foot-and-
mouth disease virus (36, 37), are known to utilize cell surface
heparan sulfate as an attachment or entry receptor.
In the present study, we investigate the role of heparan sulfate
in the binding of EV-71 to the surface of rhabdomyosarcoma
(RD) cells. We provide evidence that the ability of EV-71 to bind
to RD cells was reduced after the enzymatic removal of cell surface
heparan sulfate and through the obstruction of heparan sulfate
biosynthesis. Our results show that cell surface heparan sulfate,
and not chondroitin sulfate, serves as an attachment receptor for
EV-71.
MATERIALS AND METHODS
Reagents. Soluble GAGs (heparin sodium salt from porcine intestinal
mucosa, chondroitin sulfate sodium salt from shark cartilage, N-acetyl-
de-O-sulfated heparin sodium salt, and de-N-sulfated heparin sodium
salt), dextran sulfate sodium salt from Leuconostoc mesenteroides,
suramin, heparinase I/II/III from Flavobacterium heparinum, chondroiti-
nase ABC from Proteus vulgaris, and sodium chlorate were all purchased
from Sigma.Heparinase I from recombinantBacteroides thetaiotaomicron
was supplied by R&D Systems. An anti-EV-71 monoclonal antibody and
poly-D-lysine were purchased from Millipore, and Alexa Fluor 488-la-
beled anti-mouse IgG was purchased from Invitrogen. Anti-heparan sul-
fate peptides G1 (LRSRTKIIRIRH) and G2 (MPRRRRIRRRQK) (under-
lining indicates positively charged amino acids), described previously
(38), were synthesized by Mimotopes Pty Ltd. (Australia) with 92%
purity as determined by high-performance liquid chromatography
(HPLC). All the primers and probes were synthesized by IDT.
Cell lines and viruses. All the cell lines used in this experiment were
obtained from the American Type Culture Collection (ATCC). Human
rhabdomyosarcoma (RD; ATCC no. CCL-136) and Chinese hamster
ovary (CHO-K1; ATCC no. CCL-61) cells were grown in Dulbecco’s
modified Eagle medium (DMEM) (HyClone) supplemented with 10%
fetal bovine serum (FBS). Mutant CHO-pgsD677 (ATCC no. CRL-2244)
and CHO-pgsA745 (ATCC no. CRL-2242) cells were grown in Kaighn’s
modification of Ham’s F-12 (F-12K) medium (ATCC) supplemented
with 10% FBS. All the experiments were carried out using 1.5  104 RD
cells, unless otherwise stated. EV-71 laboratory strains BrCr (GenBank
accession number AB204852), 41 (a gift from Tan Eng Lee, Singapore
Polytechnic, Singapore) (GenBank accession number AF316321), UH1/
PM/97 (GenBank accession number AM396587), and SHA66/97 (GenBank
accession number AM396586) were propagated in RD cells in mainte-
nance medium supplemented with 2% FBS. All the other EV-71 isolates
(14716, 35017, 1687413, and 1657640) and the poliovirus (PV) vaccine
strain were obtained from theDiagnostic Virology Laboratory, University
Malaya Medical Center, Kuala Lumpur, Malaysia. Isolates 14716,
1687413, and 1657640 were all passaged once in tissue culture, while iso-
late 35017 had been passaged twice. Throughout the study, EV-71 strain
41 was used, unless otherwise stated.
TaqMan quantitative real-time PCR assay. TaqMan quantitative
real-time PCR was performed as described previously (14). Forward
primer 5=-GAGCTCTATAGGAGATAGTGTGAGTAGGG-3=, reverse
primer 5=-ATGACTGCTCACCTGCGTGTT-3=, and TaqMan probe 5=-
6-carboxyfluorescein (FAM)-ACTTACCCA/ZEN/GGCCCTGCCAGCT
CC-Iowa Black FQ-3= were used. Viral RNA samples were extracted by
using a QIAamp viral RNA minikit (Qiagen, Germany) according to
the manufacturer’s instructions. The TaqMan real-time reverse tran-
scription (RT)-PCR assay was performed with the StepOnePlus real-
time system (ABI) using the TaqMan Fast Virus 1-step master mix
(ABI), with cDNA synthesis from RNA by reverse transcription for 5
min at 50°C and subsequent amplification for 40 cycles at 95°C for 3 s
and 60°C for 30 s.
Evaluation of the role of GAGs and inhibitors in EV-71 infection of
RD cells. Viral inactivation experiments were performed by preincuba-
tion of EV-71 particles with various concentrations of GAGs (heparin,
chondroitin sulfate, de-N-sulfated heparin, and N-acetyl-de-O-sulfated
heparin) and inhibitors (dextran sulfate and suramin) for 60 min at 37°C
before inoculation of the RD cells. For cell protection studies, RD cells
were preincubatedwithGAGs, poly-D-lysine, or anti-heparan sulfate pep-
tides at various concentrations for 60 min at 37°C. The cells were washed
twice andwere subsequently infectedwith various EV-71 isolates for 1 h at
amultiplicity of infection (MOI) of 0.1. Viral infectivitywas evaluated and
quantified by TaqMan real-time PCR and a plaque assay after 24 h postin-
fection.
Inhibition of cellular GAG sulfation by sodium chlorate. Sodium
chlorate inhibition experiments were carried out in DMEM supple-
mented with 10% FBS. RD cells were cultured for 24 h in the presence of
sodium chlorate at concentrations ranging from 0 mM to 50 mM, fol-
lowed by infection using different EV-71 strains at an MOI of 0.1. The
viral titers were quantified by TaqMan quantitative real-time PCR.
siRNA silencing of the gene involved in heparan sulfate biosynthe-
sis. Small interfering RNAs (siRNAs) targeting the heparan sulfate-mod-
ifying enzyme N-deacetylase/N-sulfotransferase 1 (NDST-1) and the
heparan sulfate polymerase exostosin-1 (EXT-1) were purchased from
Santa Cruz Biotechnology. Negative-control siRNA with no homology to
any known mammalian gene was obtained from Bioneer. Different con-
centrations of the siRNAs (0 nM, 1 nM, 5 nM, 10 nM, and 20 nM in 50l
of Opti-MEM) were incubated with Lipofectamine 2000 in Opti-MEM I
(Invitrogen) for 20 min. The siRNA was then transfected into 1.0  104
RD cells for 24 h. Prior to EV-71 infection, the transfection medium was
removed, and the cells were washed twice with growth medium (DMEM
with 10% FBS) and were then incubated with the growth medium for at
least 3 h. The cells transfected with the respective siRNAs were infected
with EV-71 at an MOI of 0.1 for 1 h at room temperature. After 1 h of
incubation, the inoculum was removed, washed twice, and replaced with
maintenance medium (DMEMwith 2% FBS). The viral titers were deter-
mined at 24 h postinfection by using TaqMan quantitative real-time PCR.
Enzymatic removal of GAGs from the surfaces of RD cells. Chon-
droitinase ABC and heparinase I/II/III were reconstituted in digestion
buffer I (phosphate-buffered saline [PBS] containing 0.05 M sodium ac-
etate and 0.02% bovine serum albumin [BSA] [pH 7.5]) and digestion
buffer II (PBS containing 0.5 mM MgCl2, 0.9 mM CaCl2, and 0.1% BSA
[pH 7.5]), respectively, and various concentrations of the enzymes (50
l/well) were added to RD cells, which were then incubated for 1 h at
37°C. Cells were then washed with the respective digestion buffers and
were subsequently infected with EV-71 for 1 h at 4°C. After the incuba-
tion, the cells were washed twice with serum-free medium, and infectivity
was determined 24 h postinfection by TaqMan real-time RT-PCR.
Binding of EV-71 to GAG-deficient cell lines. RD, CHO-K1, CHO-
pgsD677, and CHO-pgsA745 cells in chamber slides (Lab-Tek) and
CellCarrier-96 plates (Perkin-Elmer) were infected with EV-71 (MOI,
100) at 4°C for an hour. After 1 h of incubation, the inocula were
removed and the cells were fixed with 4% formaldehyde. The fixed cells
were permeabilized using 0.25% Triton X-100 (Sigma) for 5 min and
were subsequently blocked with Image-iT FX signal enhancer (Invit-
rogen) for 1 h. EV-71 particles were immunostained with mouse anti-
EV-71 monoclonal antibodies (Millipore) as the primary antibodies
and 1:200-diluted Alexa Fluor 488-labeled anti-mouse IgG (Invitro-
gen) as the secondary antibody for 1 h at 37°C. For nuclear visualiza-
tion, cells were treated with 0.01% 4=,6-diamidino-2-phenylindole
(DAPI; Sigma) for 7 min at room temperature. Immunofluorescence
was detected with a Leica TCS SP5 confocal microscope (Leica Micro-
systems, Germany). The CellCarrier-96 plate was evaluated using a
Cellomics ArrayScan VTI HCS reader with Spot Detector BioApplica-
tion software (Thermo Scientific). The data are presented as the total
viral spot count per cell (calculated as the total number of fluorescent
Tan et al.
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viral spots divided by the total number of cells in the same field) and
were subsequently verified by TaqMan quantitative real-time PCR.
Binding of EV-71 particles to immobilized heparin-Sepharose
beads. Six milliliters of EV-71 or PV vaccine strain supernatant was ap-
plied to a 1-ml HiTrap Heparin HP column (GE Healthcare, Sweden)
previously equilibrated with the binding buffer (0.02M Tris-HCl, 0.14M
NaCl [pH 7.4]) at a flow rate of approximately 0.5 ml/min. After loading,
the column was washed with at least 5 to 10 column volumes of binding
buffer. The bound viral particles were eluted using the elution buffer (0.02
M Tris-HCl, 2 M NaCl [pH 7.4]). Fractions of 1 ml were collected and
analyzed by TaqMan quantitative real-time PCR and plaque assays for
EV-71 and the PV vaccine strain, respectively.
Cytotoxicity analysis. The cytotoxicities of heparin, dextran sulfate,
anti-heparan sulfate peptides, and sodium chlorate were determined us-
ing the CellTiter 96 AQueousOne solution cell proliferation assay reagent
(Promega). Briefly, various concentrations of these compounds were
added to overnight-cultured RD cells, which were then incubated over-
night. Then 20 l of the CellTiter 96 AQueous One solution cell prolifer-
ation assay reagent was added to each well. The plate was then analyzed at
an absorbance of 490 nm after 2 h of incubation at 37°C.
Three-dimensional crystal structure and sequence analysis. The
crystal structure of EV-71 (Protein Data Bank [PDB] identification code
4AED) (39) was obtained from the PDB (http://www.rcsb.org/pdb). The
3-dimensional structure of the EV-71 pentamer was built using the Deep-
View-Swiss PDB Viewer, version 4.0.4 (Swiss Institute of Bioinformatics)
(40). For sequence analysis, 174 VP1 sequences from different genotypes
(41) were downloaded from GenBank (http://www.ncbi.nlm.nih.gov
/protein/) and were aligned using ClustalW2 software (http://www.ebi.ac
.uk/tools/msa/clustalw2/).
Statistical analysis. The data presented are the means  standard
deviations (SD) obtained from at least two independent biological repli-
cates. Error bars represent the SD. Statistical significance was calculated
using the Mann-Whitney test. A P value of 0.05 was considered statis-
tically significant.
RESULTS
Inhibition of EV-71 infection by heparin, dextran sulfate, and
suramin. To determine whether surface GAGs play a significant
role in virus-receptor interactions, various concentrations of dif-
ferent GAGs were preincubated with EV-71 at anMOI of 0.1 for 1
h at 37°C before infection of RD cells. The viral titers were quan-
tified 24 h postinfection by using TaqMan quantitative real-time
PCR and plaque assays. Of the two GAGs evaluated, significant
inhibition of EV-71 by heparin and chondroitin sulfate was ob-
served only at concentrations above 500 g/ml (Fig. 1A). The
inhibitory effect of heparin was more significant, at 79.4% 
2.9%, than that of chondroitin sulfate (38.5% 6.4%) when they
were tested at a concentration of 1,000g/ml (P 0.05). A similar
inhibitory trend was observed in the plaque assays (Table 1).
To further investigate the significance of the carbohydrate
backbone for the inhibition of EV-71, polyanionic dextran sulfate
(2.3 sulfate groups/glucosyl group) and the polysulfonate phar-
maceutical suramin (6.0 sulfate groups/molecule) were used. Pre-
vious studies have shown that suramin inhibits viruses such as
dengue virus (24) and hepatitis B virus (30), which bind to cell
surface heparan sulfate. Viral inhibition increased with the con-
centration of the inhibitors tested, and at 1,000g/ml, the levels of
inhibition were 65.8%  6.7% for dextran sulfate and 63.4% 
6.1% for suramin (Table 1). However, suramin was more effec-
tive, since it was able to inhibit EV-71 infection at a concentration
as low as 20 g/ml (Fig. 1A).
Preincubation of RD cells with heparin or dextran sulfate at
concentrations from 100 to 1,000g/ml before viral infection had
FIG 1 Inhibitory effects of GAGs and inhibitors. (A) For the viral inactivation
assay, various concentrations of GAGs, polyanionic dextran sulfate, and
suramin were preincubated with EV-71 particles for 1 h at 37°C before infec-
tion of RD cells at room temperature. (B and C) For the cell protection assay,
various concentrations of GAGs (B) or of poly-D-lysine or anti-heparan sulfate
peptides, designated peptides G1 and G2 (C), were preincubated with RD cells
for 1 h at 37°C before EV-71 infection. The viral RNA was extracted and
quantified by quantitative real-time PCR 24 h postinfection.




Viral plaque Viral RNA
Heparin 95.5 0.7 79.4 2.9
Chondroitin sulfate 52.4 16.4 38.4 6.4
De-N-sulfated heparin 70.0 1.1 39.7 15.6
Dextran sulfate 95.2 0.7 65.8 6.7
Suramin 76.3 2.4 63.4 6.1
a The concentration of inhibitors used was 1,000 g/ml.
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no inhibitory effect but enhanced virus infectivity. The results
demonstrated that the inhibitory effect was due to direct interac-
tion of these compounds with the virus and not with the target
cells (Fig. 1A and B).
Neutralization of negative charges on cell surfaces reduces
EV-71 infection. To assess the important role of negative charges
carried on the cell surface in the binding of EV-71, we preincu-
batedRDcells with poly-D-lysine to neutralize negative charges on
cell surfaces before infection. As shown in Fig. 1C, poly-D-lysine
strongly decreased the level of EV-71 infection when applied at
concentrations from 1 to 5 g/ml. At 5 g/ml, the inhibition was
99.1%  0.2%. To ascertain whether the negative charge carried
by heparan sulfate present on the cell surface plays a significant
role in viral attachment, two anti-heparan sulfate peptides, G1
(LRSRTKIIRIRH) and G2 (MPRRRRIRRRQK), were evaluated
for their inhibitory effects. The inhibitory effect of G2 was signif-
icant, with viral RNA inhibition of 76.5% 26.8%at 1,000g/ml.
The G1 peptide did not inhibit EV-71 infection (Fig. 1C).
Heparin reduces the infectivity of both laboratory strains
and low-passage-number isolates. Heparin at 2,500 g/ml was
observed to have inhibitory effects both on the laboratory strains
and on the low-passage-number EV-71 isolates tested (Fig. 2). The
inhibitory effects differed between strains. The level of inhibition
of the laboratory strains ranged from 61.4% to 98.0%, while that
of the low-passage-number isolates ranged from 30.4% to 78.4%.
Interestingly, heparin failed to inhibit the PV vaccine strain even
when tested at 2,500 g/ml.
N- and O-sulfation on heparan sulfate are critical for EV-71
infection. To establish whether the degree of sulfation of hep-
arin is critical for viral inhibition, different sulfated heparin
variants were investigated. Completely desulfated heparin
failed to abolish EV-71 infection (Fig. 3A). In contrast, de-N-
sulfated heparin showed moderate inhibition (39.7% 
15.6%) at 1,000 g/ml, indicating that the degree of sulfation
within the GAG carbohydrate structure is functionally impor-
tant. The inhibition of viral plaque formation by these GAGs
and inhibitors is shown in Table 1.
To further confirm the role of the sulfation of heparan sulfate
in EV-71 attachment, we carried out EV-71 infection of RD cells
grown in a medium containing 0 to 50 mM sodium chlorate. The
growth of cells in the presence of sodium chlorate, which inhibits
cellular ATP-sulfurylase, has been shown previously to reduce the
extent of sulfation of heparan sulfate by as much as 60%, and cells
with such modified cell surfaces have been used to examine the
role of GAGs in attachment by other viruses (25, 42). As shown in
Fig. 3B, sodium chlorate was found to reduce the level of EV-71
infection of RD cells significantly, in a dose-dependent manner,
FIG 2 Inhibitory effects of heparin on EV-71 isolates and the PV vaccine
strain. EV-71 and PV particles were pretreated with heparin at a final concen-
tration of 2,500 g/ml for 1 h at 37°C before infection of RD cells. The low-
passage-number EV-71 isolates (14716, 35017, 1657640, and 1687413) and the
PV vaccine strain were obtained from the Diagnostic Virology Laboratory,
University Malaya Medical Center. The titers of EV-71 and the PV vaccine
strain were quantified 24 h postinfection by TaqMan quantitative real-time
PCR and plaque assays, respectively.
FIG 3 (A) EV-71 was preincubated with various concentrations of heparin
and desulfated heparin variants for 1 h at 37°C before infection of RD cells.
(B) Inhibitory effect of sodium chlorate on different EV-71 strains in RD
cells. RD cells were pretreated with increasing concentrations (0 mM, 10
mM, 30 mM, and 50 mM) of sodium chlorate for 24 h before EV-71 infec-
tion at an MOI of 0.1. (C) Transient siRNA knockdown of NDST-1 and
EXT-1 expression. NDST-1, EXT-1, and negative-control siRNAs in the
Lipofectamine 2000 reagent were transfected into RD cells for 24 h before
EV-71 infection. The viral load was determined 24 h postinfection by TaqMan
quantitative real-time PCR.
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with all strains tested. At 50mM, sodium chlorate inhibited infec-
tion with EV-71 strains 41, UH1, SHA66, and BrCr; the percent-
ages of viral RNA inhibition were 92.7% 2.7%, 79.0% 3.3%,
83.2%  4.2%, and 61.5%  5.5%, respectively. To rule out the
possibility that the reduction in the level of EV-71 infection was
due to cytotoxicity, the cytotoxicity of sodium chlorate was eval-
uated by the commercially available 3-(4,5-dimethyl-2-thiazolyl)-
2,5-diphenyl-2H-tetrazolium bromide (MTT) assay. The data re-
vealed that sodium chlorate has minimal cytotoxicity at 50 mM.
To further confirm that heparan sulfate plays an important
role in EV-71 infection, expression of the NDST-1 and EXT-1
genes was transiently knocked down using siRNA. NDST-1 is a
heparan sulfate modification enzyme that removes N-acetyl
groups from selectedN-acetylglucosamine (GlcNAc) residues and
replaces themwith sulfate groups (43). EXT-1 is a heparan sulfate
polymerase that adds alternating units of glucuronic acid (GlcA)
andGlcNAc to the nonreducing end of the chain. As shown in Fig.
3C, transient knockdownofNDST-1 and EXT-1 expression in RD
cells significantly reduced the level of EV-71 infection, with per-
centages of inhibition as high as 80.1%  7.7% and 57.2% 
19.1%, respectively, at 20 nM siRNA. However, the negative-con-
trol siRNA was unable to reduce EV-71 infection.
Enzymatic removal of heparan sulfate from the cell surface
reduces the levels of EV-71 binding and infection of RDcells.To
identify the type of GAG that is responsible for the binding of
EV-71 to RD cells, we examined EV-71 binding to cells after en-
zymatic removal of cell surface GAGs by chondroitinase ABC and
heparinase I/II/III digestion. Heparinase I degrades heparin and
highly sulfated domains in heparan sulfate, while heparinase II
cleaves both heparin and heparan sulfate, and heparinase III spe-
cifically degrades heparan sulfate (24). Treatment of RD cells with
each of the heparinases at 2.5 mIU/ml and 5.0 mIU/ml for 1 h at
37°C was found to reduce viral RNA levels and plaque formation
significantly (data not shown), in a dose-dependent manner, 24 h
postinfection. Treatment of RD cells with heparinases I, II, and III
at 5.0 mIU/ml significantly inhibited EV-71 RNA levels by
68.6% 6.2%, 91.7% 4.1%, and 82.2% 11.7%, respectively
(Fig. 4A). Removal of cell surface chondroitin sulfate by chon-
droitinase ABC failed to inhibit EV-71 infection (Fig. 4A), even
when chondroitinase ABC was tested at concentrations as high as
20 mIU/ml (data not shown). Removal of cell surface heparan
sulfate significantly reduced the infectivities of the different EV-71
strains tested, but not that of the PV vaccine strain (Fig. 4B). Re-
moval of surface heparan sulfate, but not chondroitin sulfate, was
found to significantly reduce EV-71 attachment to the surfaces of
RD cells (Fig. 4C).
Significant reduction in the level of EV-71 binding to GAG-
deficient CHO cells.CHO cells with defects in the biosynthesis of
GAGs have been used extensively to demonstrate the involvement
of heparan sulfate as the receptor for the binding of various viruses
(29, 30, 33, 42, 44). Mutant CHO-pgsD677 cells are deficient in
N-acetylglucosaminyltransferase and glucuronosyltransferase ac-
tivities, which are required for heparan sulfate polymerization,
and thus completely lack heparan sulfate; these cells also produce
levels of chondroitin sulfate 3- to 4-fold higher than those in wild-
type CHO-K1 cells (45). Mutant CHO-pgsA745 cells are deficient
in the enzyme UDP-D-xylose:serine-1,3-D-xylosyltransferase,
which catalyzes the first sugar transfer reaction inGAG formation,
and thus completely lack GAGs (46). To investigate whether
EV-71 binds differently to these cell lines, cells were seeded in
CellCarrier-96 plates and chamber slides and were infected with
EV-71 at anMOI of 100 for 1 h at 4°C. As shown in Fig. 5A and B,
significantly fewer viral particles were attached to CHO-pgsD677
and CHO-pgsA745 cells than to wild-type CHO-K1 cells, which
expressed heparan sulfate (P 0.001). CHO-pgsD677 and CHO-
pgsA745 cells showed reduced binding levels of 46.7% and 41.6%,
respectively, compared to 100% for CHO-K1 cells. Interestingly,
more viral particles were bound to RD cells than to CHO-K1 cells.
Binding of EV-71 to immobilized heparin-Sepharose. To
characterize the interaction of EV-71 particles withGAGs, a virus-
containing supernatant was applied to a heparin affinity chroma-
tography column. EV-71 particles bound to immobilized hepa-
rin-Sepharose under physiological salt conditions (0.14 M NaCl)
and were eluted by 2 M NaCl. The virus titers in each fraction
collected were quantified by TaqMan quantitative real-time PCR.
As shown in Fig. 6, most of the EV-71 particles were detected in all
the eluates following the application of 2 M NaCl. The EV-71
particles present in eluate 1were concentrated asmuch as 4.1-fold.
In a control experiment, we used a column packedwith Sepharose
alone and found no binding of EV-71 particles to the column
(data not shown). The results confirm that EV-71 particles bind to
heparin andwere eluted by high salt concentrations. In contrast to
EV-71, the PV vaccine strain did not interact with heparin-Sep-
harose, and most of the PV particles were detected in the flow-
through fraction (Fig. 6).
Symmetry clustering of highly conserved amino acids
Arg166,Lys242, andLys244ofVP1 in theEV-71pentamer struc-
ture. To determine the possible heparan sulfate binding site(s) on
EV-71 particles, the 3-dimensional crystal structure of EV-71 was
built using theDeepView-Swiss PDB viewer (40). As shown in Fig.
7A, amino acids Arg166, Lys242, and Lys244 are arranged sym-
metrically in the 5-fold axis of the EV-71 pentamer structure.
These amino acids are also located at positions that are highly
exposed on the surface of the EV-71 particle (Fig. 7B). All these
amino acids were highly conserved across all EV-71 genotypes
except for Lys244, where lysine (K) was replaced by glutamic acid
(E) in genotype A (Fig. 7C). This symmetrically arranged cluster-
ing of positively charged amino acids could serve as the binding
site for heparan sulfate.
DISCUSSION
Virus receptorsmay be one of the determinants of virus host range
and tissue tropism (5). Receptors that are known to bind to EV-71
have been identified over the past few years. P-selectin glycopro-
tein ligand-1 (PSGL-1) was the first to be discovered as the EV-71
receptor. However, PSGL-1 is selectively expressed only in neu-
trophils, monocytes, and most lymphocytes (6). The second re-
ceptor, reported by Yamayoshi et al. (9), was human SCARB2,
which is expressed on most types of cells (7). EV-71 binds to the
SCARB2 receptor and is then internalized through clathrin-medi-
ated endocytosis (47, 48). However, blocking of these receptors
did not abolish EV-71 infection, and this finding led to the discov-
ery of the third receptor, annexin II. Pretreatment of host cells
with an anti-annexin II antibody was found to reduce the level of
viral attachment. Preincubation of EV-71 with annexin II also
reduced the level of EV-71 infection (12).
Besides these known receptors for EV-71, sialylated glycans
were reported by Yang et al. (11) as receptors for EV-71. Treat-
ment of RD, SK-N-SH, and DLD-1 cells with neuraminidase was
found to reduce the ability of EV-71 to bind to the cell surface,
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confirming that EV-71 utilizes sialylated glycans as attachment
factors (10). We have shown in this study that, in addition to the
four receptors published to date, cell surface heparan sulfate is
required for EV-71 attachment. The level of EV-71 infection of
RD cells was significantly reduced when EV-71 particles were pre-
treated with soluble heparin, dextran sulfate, or suramin. How-
ever, preincubation of RD cells with heparin or dextran sulfate did
not inhibit EV-71 infection but unexpectedly enhanced it. This
may be caused by the creation of artificial binding sites through
accumulation of heparin and dextran sulfate on the surfaces of
cells (30, 49). These findings imply that heparin or dextran sulfate
could bind to the positively charged surfaces of viral particles and
prevent the interaction of viral particles with the cell surface, as
demonstrated for foot-and-mouth disease virus (50). Removal of
cell surface heparan sulfate using each of the heparinases (I, II, and
III) also reduced the ability of EV-71 to bind to and infect RD cells,
further confirming the important role of heparan sulfate in EV-71
infection. The possible involvement of chondroitin sulfate as a
receptor for attachment was excluded based on the evidence that
enzymatic removal of chondroitin sulfate did not impair EV-71
infection.
In the present study, we demonstrated that EV-71 can bind to
CHO cells. However, CHO cells defective in the biosynthesis of
heparan sulfate and chondroitin sulfate exhibited a reduced ability
to bind to EV-71, further supporting the role of heparan sulfate in
EV-71 infection.While EV-71 could bind to the CHO-K1 cells, no
infection was observed, suggesting that EV-71 failed to internalize
so as to initiate infection. TMEVGDVII bound to heparan sulfate
has been postulated to use protein entry receptors for virus inter-
nalization (27). A similar mechanism could be utilized by EV-71.
EV-71 particles bound to heparan sulfate may need to interact
with known receptors, such as SCARB2 and sialylated glycan, or
with an unknown protein entry receptor, to gain entry into
cells. CHO cells, of hamster origin, may have a different
FIG 4 Treatment of RD cells with heparinase or chondroitinase ABC. (A) Inhibitory effects of heparinase I/II/III and chondroitinase ABC on EV-71 infection.
RD cells were pretreated with heparinase or chondroitinase ABC for 1 h at 37°C before EV-71 infection at an MOI of 0.1. The viral RNA was extracted and
evaluated by TaqMan quantitative real-time PCR. (B) Inhibitory effect of heparinase I on different EV-71 strains and the PV vaccine strain. (C) Confocal
microscopy analysis (with a 40 objective) of EV-71 binding assays after heparinase I or chondroitinase ABC treatment. EV-71 particles were stained with a
monoclonal anti-EV-71 antibody and were subsequently stained with Alexa Fluor 488-labeled anti-mouse IgG. Nuclei were stained with DAPI. EV-71 particles
and nuclei are shown in green and blue, respectively.
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SCARB2, since it has been reported that EV-71 binding do-
mains in human SCARB2 and murine SCARB2 are different
(51). In this study, we also showed that EV-71 was still able to
bind to the CHO mutant completely lacking in heparan sulfate
and chondroitin sulfate, which further suggests that multiple
receptors are involved during EV-71 infection. This view is
similar to what has been reported for several viruses that use
heparan sulfate (27, 52, 53).
Heparan sulfate is expressed by all cell types.However, heparan
sulfate expressed on different types of cells shows variations in
structure, with differences in the degrees of sulfation, chain
length, and the position of the sulfate group (54). Our data dem-
onstrated that highly sulfated heparin could inhibit EV-71 infec-
tion, whereas decreased sulfation on heparin led to a loss of EV-71
inhibition. Completely desulfated heparin was found to have no
inhibitory effect. These findings suggest that structural differences
in the heparan sulfate present in different cell types could lead to
differences in susceptibility to infection, which may contribute to
the selective tropism of EV-71 (37).
Heparan sulfate binding could arise from adaptation to the
cells in which isolates were propagated. Culture adaptations of
heparan sulfate usage in picornaviruses (55, 56), flaviviruses (57),
and alphaviruses (58) have been demonstrated. In vitro cultivation
of viruses has been shown to rapidly select amino acid substitu-
tions that increase the net positive charge of the envelope protein
(59). However, the heparan sulfate binding phenotype has also
been documented for clinical isolates of the porcine circoviruses
(53) and echoviruses (33). In the present study, we showed that
heparin was able to inhibit EV-71 isolates that had been passaged
only once in tissue culture, suggesting that heparan sulfate bind-
ing phenotypes are not likely to be due to culture adaptation of
EV-71. We also provide evidence that heparin failed to inhibit the
infection of RD cells with the PV vaccine strain, further strength-
ening our view that EV-71 binds to heparan sulfate.
Furthermore, we also presented evidence that EV-71 binds to
heparin-Sepharose under physiological salt concentrations and
that the interaction could be disrupted by high salt concentra-
tions. This finding suggests that EV-71–heparin interactions in-
volve mainly electrostatic charge interactions. Replacement of a
single positively charged amino acid with another amino acid is
sufficient to retard the heparin binding phenotype in TMEVGDVII
FIG 5 Binding of EV-71 to CHO-K1 and CHOmutant cells. CHO-K1 cells and cells of CHOmutants defective in proteoglycan synthesis were assessed for their
abilities to bind to EV-71. The CHO-pgsA745 cell line lacks heparan sulfate and chondroitin sulfate proteoglycans, while the CHO-pgsD677 cell line lacks
heparan sulfate proteoglycan but produces 15% of normal proteoglycans. The binding of EV-71 to parental andmutant CHO cells was assayed by using confocal
microscopic analysis (A) and a Cellomics ArrayScan VTI HCS reader with Spot Detector BioApplication software (B) and was verified by TaqMan quantitative
real-time PCR.
FIG 6 Binding of EV-71 and PV to an immobilized heparin-Sepharose col-
umn. EV-71 and PV supernatants were passed through a column of immobi-
lized heparin-Sepharose and were eluted with 2 M NaCl. The titers of EV-71
and the PV vaccine strain from each fraction were quantified by TaqMan
quantitative real-time PCR and plaque assays, respectively. EV-71 levels are
presented as viral RNA copies per milliliter, and levels of the PV vaccine strain
are presented as PFU per milliliter. Error bars represent means SD for each
fraction.
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and coxsackievirus A9 (27, 34, 60). Thus, positively charged
amino acids on the surfaces of viral particles are critical for the
heparin binding phenotype. Sequence analysis of the VP1 capsid
protein revealed two possible heparan sulfate mimic binding do-
mains, from residues 120 to 123 (-RRKV-) and residues 241 to 244
(-SKSK-). Interestingly, our previous study has shown that pep-
tides with these heparan sulfate binding domains exhibited signif-
icant antiviral activities against EV-71 infection in RD cells (14),
suggesting that the inhibitory effect could have resulted from di-
rect binding to heparan sulfate and blocking of viral attachment.
Heparan sulfate-interacting regions could be linear heparan sul-
fate binding domains, as well as clusters of basic residues that arise
as a result of the 3-dimensional structure, as shown for foot-and-
mouth disease virus and coxsackievirus A9 (34, 50). With the re-
cently available crystal structure of EV-71, the electrostatic surface
of EV-71was determined (61). A few conserved positively charged
amino acids (Arg166, Lys242, and Lys244) were clustered sym-
metrically at the 5-fold axis of the EV-71 pentamer. The linear
arrangement of these amino acids in the cluster could also be
significant for the interactions. These amino acids were also lo-
cated on the surfaces of EV-71 particles. These findings suggest
that the interaction could be due to the electrostatic interactions
between these clusters of basic amino acids arranged in a 3-dimen-
sional array on the virions and concentrated negative charges on
the sulfated heparan sulfate chain.
In this study, we have shown that EV-71 particles utilized cell
surface heparan sulfate as an attachment receptor. Although the
exact mechanism of interaction of EV-71 particles with negatively
FIG 7 Three-dimensional pentameric structure and sequence alignment of EV-71. The structure of the EV-71 pentamer was generated using the DeepView-
Swiss PDB viewer. The molecular structures of EV-71 VP1, VP2, VP3, and VP4 are presented in blue, green, red, and purple, respectively. The amino acids
Arg166, Lys242, and Lys244 are presented in yellow,white, and light blue, respectively. (A) Top viewof the EV-71 pentamer. (B) Side viewof the EV-71 pentamer.
(C)Histogram showing sequence consensus in the VP1 region of EV-71. A total of 174 sequences were aligned and analyzed using ClustalW2. The arbitrary scale
is shown at the left of the histogram; 1.0 denotes perfect consensus at a given amino acid site across all entries. The alignments of Arg166, Lys242, and Lys244 in
representative EV-71 strains from genotypes A, B, and C are shown above the histogram.
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charged heparan sulfate on the cell surface remains unclear, deter-
mination of the molecular basis of the virus-receptor interaction
in target cells will be useful for understanding the pathogenicity of
EV-71 and for the development of antiviral agents against EV-71.
ACKNOWLEDGMENTS
We acknowledge Lim Fei Tieng (Hi-Tech Instruments Sdn Bhd, Malay-
sia) for assistance in the confocal microscopy analysis.
This work was supported by University of Malaya research grants
(RG245/10HTMandRG298/11HTM),University ofMalayaHigh Impact
research grants (E000013-20001 and UM.C/625/1/HIR/014), a Funda-
mental Research Grant Scheme (FP015/2012A) from the Ministry of Ed-
ucation,Malaysia, a postgraduate research grant (PV013/2012A) from the
University of Malaya, and a Sunway University research grant (SHNS-
0111-01).
REFERENCES
1. Brown BA, Pallansch MA. 1995. Complete nucleotide sequence of en-
terovirus 71 is distinct from poliovirus. Virus Res. 39:195–205.
2. Chan YF, Sam IC, Wee KL, AbuBakar S. 2011. Enterovirus 71 in Ma-
laysia: a decade later. Neurol. Asia 16:1–15.
3. Ooi MH, Wong SC, Lewthwaite P, Cardosa MJ, Solomon T. 2010.
Clinical features, diagnosis, and management of enterovirus 71. Lancet
Neurol. 9:1097–1105.
4. Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH.
2010. Virology, epidemiology, pathogenesis, and control of enterovirus
71. Lancet Infect. Dis. 10:778–790.
5. Haywood AM. 1994. Virus receptors: binding, adhesion strengthening,
and changes in viral structure. J. Virol. 68:1–5.
6. Nishimura Y, Shimojima M, Tano Y, Miyamura T, Wakita T, Shimizu
H. 2009. Human P-selectin glycoprotein ligand-1 is a functional receptor
for enterovirus 71. Nat. Med. 15:794–797.
7. Yamayoshi S, Iizuka S, Yamashita T, Minagawa H, Mizuta K, Okamoto
M, Nishimura H, Sanjoh K, Katsushima N, Itagaki T, Nagai Y, Fujii K,
Koike S. 2012. Human SCARB2-dependent infection by coxsackievirus
A7, A14, and A16 and enterovirus 71. J. Virol. 86:5686–5696.
8. Yamayoshi S, Koike S. 2011. Identification of a human SCARB2 region
that is important for enterovirus 71 binding and infection. J. Virol. 85:
4937–4946.
9. Yamayoshi S, Yamashita Y, Li J, Hanagata N, Minowa T, Takemura T,
Koike S. 2009. Scavenger receptor B2 is a cellular receptor for enterovirus
71. Nat. Med. 15:798–801.
10. Su PY, Liu YT, Chang HY, Huang SW, Wang YF, Yu CK, Wang JR,
Chang CF. 2012. Cell surface sialylation affects binding of enterovirus 71
to rhabdomyosarcoma and neuroblastoma cells. BMCMicrobiol. 12:162.
doi:10.1186/1471-2180-12-162.
11. Yang B, Chuang H, Yang KD. 2009. Sialylated glycans as receptor and
inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol. J.
6:141. doi:10.1186/1743-422X-6-141.
12. Yang SL, Chou YT, Wu CN, Ho MS. 2011. Annexin II binds to capsid
protein VP1 of enterovirus 71 and enhances viral infectivity. J. Virol. 85:
11809–11820.
13. WuKX, NgMM, Chu JJ. 2010. Developments towards antiviral therapies
against enterovirus 71. Drug Discov. Today 15:1041–1051.
14. Tan CW, Chan YF, Sim KM, Tan EL, Poh CL. 2012. Inhibition of
enterovirus 71 (EV-71) infections by a novel antiviral peptide derived
from EV-71 capsid protein VP1. PLoS One 7:e34589. doi:10.1371/
journal.pone.0034589.
15. Lin TY, Chu C, Chiu CH. 2002. Lactoferrin inhibits enterovirus 71
infection of human embryonal rhabdomyosarcoma cells in vitro. J. Infect.
Dis. 186:1161–1164.
16. Weng TY, Chen LC, Shyu HW, Chen SH, Wang JR, Yu CK, Lei HY, Yeh
TM. 2005. Lactoferrin inhibits enterovirus 71 infection by binding to VP1
protein and host cells. Antiviral Res. 67:31–37.
17. Pourianfar HR, Poh CL, Fecondo J, Grollo L. 2012. In vitro evaluation of
the antiviral activity of heparan sulfate mimetic compounds against en-
terovirus 71. Virus Res. 169:22–29.
18. Honke K, Taniguchi N. 2002. Sulfotransferases and sulfated oligosaccha-
rides. Med. Res. Rev. 22:637–654.
19. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. 1998. Glycosamin-
oglycan-protein interactions: definition of consensus sites in glycosami-
noglycan binding proteins. Bioessays 20:156–167.
20. Laquerre S, Argnani R, Anderson DB, Zucchini S, Manservigi R, Glo-
rioso JC. 1998. Heparan sulfate proteoglycan binding by herpes simplex
virus type 1 glycoproteins B and C, which differ in their contributions to
virus attachment, penetration, and cell-to-cell spread. J. Virol. 72:6119–
6130.
21. WuDunn D, Spear PG. 1989. Initial interaction of herpes simplex virus
with cells is binding to heparan sulfate. J. Virol. 63:52–58.
22. Mondor I, Ugolini S, Sattentau QJ. 1998. Human immunodeficiency
virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120
dependent and requires cell surface heparans. J. Virol. 72:3623–3634.
23. Roderiquez G, Oravecz T, Yanagishita M, Bou-Habib DC, Mostowski
H, Norcross MA. 1995. Mediation of human immunodeficiency virus
type 1 binding by interaction of cell surface heparan sulfate proteoglycans
with the V3 region of envelope gp120-gp41. J. Virol. 69:2233–2239.
24. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ,
Marks RM. 1997. Dengue virus infectivity depends on envelope protein
binding to target cell heparan sulfate. Nat. Med. 3:866–871.
25. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M. 2001. Human
papillomavirus infection requires cell surface heparan sulfate. J. Virol.
75:1565–1570.
26. Chung CS, Hsiao JC, Chang YS, Chang W. 1998. A27L protein mediates
vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72:
1577–1585.
27. Reddi HV, Lipton HL. 2002. Heparan sulfate mediates infection of high-
neurovirulence Theiler’s viruses. J. Virol. 76:8400–8407.
28. Dechecchi MC, Melotti P, Bonizzato A, Santacatterina M, Chilosi M,
Cabrini G. 2001. Heparan sulfate glycosaminoglycans are receptors suf-
ficient to mediate the initial binding of adenovirus types 2 and 5. J. Virol.
75:8772–8780.
29. Summerford C, Samulski RJ. 1998. Membrane-associated heparan sul-
fate proteoglycan is a receptor for adeno-associated virus type 2 virions. J.
Virol. 72:1438–1445.
30. Schulze A, Gripon P, Urban S. 2007. Hepatitis B virus infection initiates
with a large surface protein-dependent binding to heparan sulfate pro-
teoglycans. Hepatology 46:1759–1768.
31. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H,
Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von
Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis
C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J.
Biol. Chem. 278:41003–41012.
32. Byrnes AP, Griffin DE. 1998. Binding of Sindbis virus to cell surface
heparan sulfate. J. Virol. 72:7349–7356.
33. Goodfellow IG, Sioofy AB, Powell RM, Evans DJ. 2001. Echoviruses
bind heparan sulfate at the cell surface. J. Virol. 75:4918–4921.
34. McLeish NJ, Williams CH, Kaloudas D, Roivainen M, Stanway G. 2012.
Symmetry-related clustering of positive charges is a commonmechanism
for heparan sulfate binding in enteroviruses. J. Virol. 86:11163–11170.
35. Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M.
2006. N- and 6-O-sulfated heparan sulfates mediate internalization of
coxsackievirus B3 variant PD into CHO-K1 cells. J. Virol. 80:6629–6636.
36. Harwood LJ, Gerber H, Sobrino F, Summerfield A, McCullough KC.
2008. Dendritic cell internalization of foot-and-mouth disease virus: in-
fluence of heparan sulfate binding on virus uptake and induction of the
immune response. J. Virol. 82:6379–6394.
37. Jackson T, Ellard FM, Ghazaleh RA, Brookes SM, Blakemore WE,
Corteyn AH, Stuart DI, Newman JW, King AM. 1996. Efficient infection
of cells in culture by typeO foot-and-mouth disease virus requires binding
to cell surface heparan sulfate. J. Virol. 70:5282–5287.
38. Tiwari V, Liu J, Valyi-Nagy T, Shukla D. 2011. Anti-heparan sulfate
peptides that block herpes simplex virus infection in vivo. J. Biol. Chem.
286:25406–25415.
39. Plevka P, Perera R, Cardosa J, Kuhn RJ, Rossmann MG. 2012. Crystal
structure of human enterovirus 71. Science 336:1274. doi:10.1126/
science.1218713.
40. Guex N, Peitsch MC. 1997. SWISS-MODEL and the Swiss-PdbViewer:
an environment for comparative protein modeling. Electrophoresis 18:
2714–2723.
41. Chan YF, Sam IC, AbuBakar S. 2010. Phylogenetic designation of en-
terovirus 71 genotypes and subgenotypes using complete genome se-
quences. Infect. Genet. Evol. 10:404–412.
42. Guibinga GH, Miyanohara A, Esko JD, Friedmann T. 2002. Cell surface
Enterovirus 71 Binds to Cell Surface Heparan Sulfate
January 2013 Volume 87 Number 1 jvi.asm.org 619
heparan sulfate is a receptor for attachment of envelope protein-free ret-
rovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus
vectors to target cells. Mol. Ther. 5:538–546.
43. Presto J, Thuveson M, Carlsson P, Busse M, Wilen M, Eriksson I,
Kusche-Gullberg M, Kjellen L. 2008. Heparan sulfate biosynthesis en-
zymes EXT1 and EXT2 affect NDST1 expression and heparan sulfate sul-
fation. Proc. Natl. Acad. Sci. U. S. A. 105:4751–4756.
44. Vlasak M, Goesler I, Blaas D. 2005. Human rhinovirus type 89 variants
use heparan sulfate proteoglycan for cell attachment. J. Virol. 79:5963–
5970.
45. Lidholt K, Weinke JL, Kiser CS, Lugemwa FN, Bame KJ, Cheifetz S,
Massague J, Lindahl U, Esko JD. 1992. A single mutation affects both
N-acetylglucosaminyltransferase and glucuronosyltransferase activities in
a Chinese hamster ovary cell mutant defective in heparan sulfate biosyn-
thesis. Proc. Natl. Acad. Sci. U. S. A. 89:2267–2271.
46. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in
glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 82:3197–
3201.
47. Hussain KM, Leong KL, Ng MM, Chu JJ. 2011. The essential role of
clathrin-mediated endocytosis in the infectious entry of human enterovi-
rus 71. J. Biol. Chem. 286:309–321.
48. Lin YW, Lin HY, Tsou YL, Chitra E, Hsiao KN, Shao HY, Liu CC, Sia
C, Chong P, Chow YH. 2012. Human SCARB2-mediated entry and
endocytosis of EV71. PLoS One 7:e30507. doi:10.1371/journal.
pone.0030507.
49. Hilgard P, Stockert R. 2000. Heparan sulfate proteoglycans initiate den-
gue virus infection of hepatocytes. Hepatology 32:1069–1077.
50. Fry EE, Lea SM, Jackson T, Newman JW, Ellard FM, Blakemore WE,
Abu-Ghazaleh R, Samuel A, King AM, Stuart DI. 1999. The structure
and function of a foot-and-mouth disease virus-oligosaccharide receptor
complex. EMBO J. 18:543–554.
51. Chen P, Song Z, Qi Y, Feng X, Xu N, Sun Y, Wu X, Yao X, Mao Q, Li
X, Dong W, Wan X, Huang N, Shen X, Liang Z, Li W. 2012. Molecular
determinants of enterovirus 71 viral entry: cleft around GLN-172 on VP1
protein interacts with variable region on scavenge receptor B2. J. Biol.
Chem. 287:6406–6420.
52. Delputte PL, Vanderheijden N, Nauwynck HJ, Pensaert MB. 2002.
Involvement of the matrix protein in attachment of porcine reproductive
and respiratory syndrome virus to a heparin like receptor on porcine al-
veolar macrophages. J. Virol. 76:4312–4320.
53. Misinzo G, Delputte PL, Meerts P, Lefebvre DJ, Nauwynck HJ. 2006.
Porcine circovirus 2 uses heparan sulfate and chondroitin sulfate B gly-
cosaminoglycans as receptors for its attachment to host cells. J. Virol.
80:3487–3494.
54. Shi X, Zaia J. 2009. Organ-specific heparan sulfate structural phenotypes.
J. Biol. Chem. 284:11806–11814.
55. Escarmis C, Carrillo EC, Ferrer M, Arriaza JF, Lopez N, Tami C,
Verdaguer N, Domingo E, Franze-Fernandez MT. 1998. Rapid selection
inmodified BHK-21 cells of a foot-and-mouth disease virus variant show-
ing alterations in cell tropism. J. Virol. 72:10171–10179.
56. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW.
1997. Tissue culture adaptation of foot-and-mouth disease virus selects
viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115–
5123.
57. Lee E, Hall RA, Lobigs M. 2004. Common E protein determinants for
attenuation of glycosaminoglycan-binding variants of Japanese encepha-
litis and West Nile viruses. J. Virol. 78:8271–8280.
58. Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis
virus to BHK cells selects for use of heparan sulfate as an attachment
receptor. J. Virol. 72:7357–7366.
59. Lee E, LobigsM. 2002. Mechanism of virulence attenuation of glycosami-
noglycan-binding variants of Japanese encephalitis virus andMurray Val-
ley encephalitis virus. J. Virol. 76:4901–4911.
60. Reddi HV, Kumar AS, Kung AY, Kallio PD, Schlitt BP, Lipton HL.
2004. Heparan sulfate-independent infection attenuates high-
neurovirulence GDVII virus-induced encephalitis. J. Virol. 78:8909–
8916.
61. Wang X, Peng W, Ren J, Hu Z, Xu J, Lou Z, Li X, Yin W, Shen X, Porta
C, Walter TS, Evans G, Axford D, Owen R, Rowlands DJ, Wang J,
Stuart DI, Fry EE, Rao Z. 2012. A sensor-adaptor mechanism for entero-
virus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 19:424–
429.
Tan et al.
620 jvi.asm.org Journal of Virology
